Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.
about
Validation of copy number variants associated with prostate cancer risk and prognosis.Transcriptional regulation and its misregulation in disease.Domestic dogs and cancer research: a breed-based genomics approach.Role of non-coding sequence variants in cancer.Impact of constitutional copy number variants on biological pathway evolutionIntegrative analysis of transcriptional regulatory network and copy number variation in intrahepatic cholangiocarcinoma.In-silico identification and functional validation of allele-dependent AR enhancers.Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer.Tracking Cancer Genetic Evolution using OncoTrack.Variants at IRX4 as prostate cancer expression quantitative trait loci.Microarray analysis of copy-number variations and gene expression profiles in prostate cancer.Inherited determinants of early recurrent somatic mutations in prostate cancer.Enhancer deregulation in cancer and other diseases.Germline copy number variation analysis in Finnish families with hereditary prostate cancer.General assessment of copy number variation in normal and tumor tissues of the domestic dog (Canis lupus familiaris).Germline copy number variations are associated with breast cancer risk and prognosis.Genome-wide Association Study (GWAS) of Germline Copy Number Variations (CNVs) Reveal Genetic Risks of Prostate Cancer in Chinese population.Identification of human glycosyltransferase genes expressed in erythroid cells predicts potential carbohydrate blood group loci.Early synergistic interactions between the HPV16‑E7 oncoprotein and 17β-oestradiol for repressing the expression of Granzyme B in a cervical cancer model.
P2860
Q33927097-BE1C9232-B52A-44F2-B4C7-3459339C45E7Q34036033-982DB090-00FF-41AE-B36F-0040E6073B86Q34152285-75533827-72DB-4F8F-995D-2D87FAC8698AQ34509633-57ED4F51-E2C4-4950-849E-2671B0C32664Q34559752-CAA348C6-1B02-4876-81EA-B5C3D6F17E91Q35181521-74CB4134-AE47-4F52-84D5-C753D16CE44FQ35741562-D72780C4-CC18-454C-822D-8CA34CB626DEQ36848024-17EA4C93-6B57-43E6-A075-88578436C80EQ37093114-CE0D4D08-A852-4F23-8B16-1A5E097E5826Q37636770-9FF7F402-83EA-4B50-8D50-B01CDC30807EQ38682456-F85DE59D-5977-452F-BE88-3FECA8E97EC6Q38701501-B60ACF9E-673C-4B39-905D-9CAE438E0DCBQ38826989-630D35CC-D856-44AD-940E-432B800293F8Q41137258-5301D8A4-4BCE-41DD-BBAB-CEAF51E107BAQ46927026-61A79E05-3A43-4796-B906-162A51A843FCQ47425936-BAA8DC25-0A3D-4043-BA8A-58DD14F53290Q54247816-A3D0FB0A-93F2-4DE6-B261-2E0A18D568AAQ55031960-A3C4FC83-235D-4A70-87CA-16A975110CD6Q55381492-3E66EDDE-4E1D-4278-8B51-9FB56E226685
P2860
Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Identification of functionally ...... ted with prostate cancer risk.
@ast
Identification of functionally ...... ted with prostate cancer risk.
@en
type
label
Identification of functionally ...... ted with prostate cancer risk.
@ast
Identification of functionally ...... ted with prostate cancer risk.
@en
prefLabel
Identification of functionally ...... ted with prostate cancer risk.
@ast
Identification of functionally ...... ted with prostate cancer risk.
@en
P2093
P2860
P50
P356
P1476
Identification of functionally ...... ted with prostate cancer risk.
@en
P2093
Arul M Chinnaiyan
Birgit Stenzel
Charles Lee
Chen X Chen
David S Rickman
Derek A Oldridge
Dimple Chakravarty
Douglas S Scherr
Georg Bartsch
Georg Schaefer
P2860
P304
P356
10.1073/PNAS.1117405109
P407
P577
2012-04-10T00:00:00Z